1.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TPST?
Forum
Prognose
Aktiensplit
Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten
Tempest Therapeutics Inc. (TPST) Q1 2026 Earnings: Significant EPS Miss with No Revenue; Stock Edges UpInterim Report - Newser
Tempest Therapeutics, Inc. 8-K Filing Details and Entity Information for May 19, 2026 - Minichart
Tempest Therapeutics (TPST) Edges Higher as Biotech Sector Shows Renewed InterestDiamond Pattern - Newser
Tempest Therapeutics announces resignation of three board members By Investing.com - Investing.com Australia
Tempest Therapeutics announces resignation of three board members - Investing.com
Tempest Therapeutics Faces Nasdaq Listing and Governance Risks - TipRanks
Tempest Therapeutics Announces Multiple Board Director Resignations - TipRanks
Tempest Therapeutics receives Nasdaq notice for listing deficiencies - Investing.com UK
Tempest Therapeutics receives Nasdaq notice for listing deficiencies By Investing.com - Investing.com Canada
Nasdaq flags Tempest Therapeutics (NASDAQ: TPST) on equity and board gaps - Stock Titan
[8-K] Tempest Therapeutics, Inc. Reports Material Event - Stock Titan
Tempest Therapeutics (TPST) Stock: Jumps +3.65%, Approaching $1.93 2026-05-20Percent Below MA - Newser
Press Releases about Tempest Therapeutics, Inc.Common Stock - The Chronicle-Journal
Tempest Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Tempest Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tempest Therapeutics (NASDAQ: TPST) Q1 2026 loss widens on CAR-T deal charges and low cash - Stock Titan
Tempest Therapeutics reports Q1 2026 net loss of $27.7M, cash $1.8M - TradingView
Tempest Therapeutics Q1 net loss widens on asset acquisition costs - TradingView
Tempest Therapeutics (TPST) posts $27.7M loss, highlights 100% CAR‑T responses - Stock Titan
Tempest CAR-T trials log 100% response in 15 patients - Stock Titan
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
MSN Money - MSN
TradingKey - TradingKey
Tempest Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Tempest Therapeutics Showcases Strong TPST-2003 CAR-T Data - TipRanks
Tempest presents TPST-2003 interim data: 100% CR in 15 CAR-T‑naïve patients, median PFS 23.1 months - TradingView
Tempest Therapeutics | 8-K: Current report - Moomoo
TPST-2003 delivers 100% CRs in rrMM, Tempest (NASDAQ: TPST) says - Stock Titan
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting - GlobeNewswire
TPST Tempest Therapeutics tops Q4 2025 EPS estimates, shares jump more than 14 percent in today’s trading.Trending Buy Opportunities - Newser
TPST Q1'26 Earnings: revenue estimate is 0 USD - TradingView
After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - GlobeNewswire
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):